Core Insights - JD Health hosted the first "Scientific Liver Protection, Healthy Future" industry forum, releasing the "2025 Scientific Liver Protection Consumer Insight Report" in collaboration with Zhongkang Technology [1] Market Trends - The report indicates that liver protection drugs are characterized by high average transaction value and high repurchase frequency, driving continuous market expansion [1] - JD Health's data shows that the sales growth rate of liver protection drugs is expected to reach 26% year-on-year in 2024 [1] Consumer Behavior - Patients spend an average of over 1800 yuan annually on liver protection drugs, with an average transaction value exceeding 260 yuan [1] - The repurchase rate for these drugs is over 50%, with an average of nearly 7 repurchases per year per patient [1] Online Consultation Growth - JD Internet Hospital reports a significant increase in online consultations for liver diseases, with a growth rate exceeding 67% from Q2 2024 to Q2 2025 [1] Strategic Goals - JD Health aims to leverage its platform capabilities and resources to focus on early screening, prevention, and treatment of liver diseases, collaborating with partners to build a more comprehensive disease prevention and patient service system [1]

Core Viewpoint - The article highlights the significant role of JD Health in promoting liver health awareness and improving liver disease prevention and treatment through its digital healthcare services and pharmaceutical supply chain advantages [2][3][4]. Group 1: Industry Context - The number of liver disease patients in China is substantial, including carriers of viral hepatitis (HBV/HCV), long-term alcohol consumers, individuals with metabolic syndrome, and drug abusers [2]. - The liver performs over 500 essential physiological functions daily, and its health directly impacts overall quality of life [2]. Group 2: Company Initiatives - JD Health hosted the "Scientific Liver Protection, Healthy Future" industry forum to showcase its efforts in liver disease management and support for pharmaceutical companies [2]. - JD Health has established a comprehensive digital service system covering the entire liver disease management cycle, leveraging its pharmaceutical supply chain and digital capabilities [3]. - The company reported a more than 40% year-on-year increase in sales of antiviral and liver-protecting traditional Chinese medicine in the past year, particularly in lower-tier markets [3]. Group 3: Consumer Trends - A report released by JD Health and Zhongkang Technology indicates a growing trend in liver health product consumption, with a projected 26% year-on-year growth in 2024 [4]. - Patients are spending an average of over 1,800 yuan annually on liver health products, with a high repurchase rate exceeding 50% and an average of nearly 7 purchases per year [4]. Group 4: Future Directions - JD Health is forming a "Scientific Liver Protection" alliance with various pharmaceutical companies to enhance public awareness of liver diseases and promote standardized health education [5]. - The company aims to build a more comprehensive disease prevention and patient service system, focusing on early screening and treatment of liver diseases [5].

Group 1 - The core viewpoint of the article highlights the growing market for liver health products, driven by high customer spending and frequent repurchases, with a projected sales growth of 26% in 2024 for liver health medications [1] - The average annual expenditure for patients on liver health products exceeds 1800 yuan, with an average transaction value of over 260 yuan and a repurchase rate exceeding 50%, indicating a strong consumer commitment [1] - The number of online consultations for liver disease is increasing significantly, with a growth rate of over 67% from Q2 2024 to Q2 2025 [1] Group 2 - Experts emphasize the importance of raising public awareness about liver health and promoting early screening and treatment as key strategies in liver disease prevention [2] - Pharmaceutical companies are committed to increasing R&D investments in liver disease prevention and treatment, with innovative therapies being developed, such as the "dual-antibody therapy" targeting liver fibrosis [2] - Internet medical platforms are seen as crucial in addressing patient pain points by integrating screening, diagnosis, standardized treatment, and management [2] Group 3 - JD Health's sales of antiviral drugs and liver health traditional Chinese medicine have seen over 40% year-on-year growth, particularly in lower-tier markets [3] - JD Health has expanded its home testing services for liver function and hepatitis B screening, now covering 23 cities nationwide, enhancing accessibility for patients [3]